Dissociated response to immune checkpoint inhibition in head and neck squamous cell carcinoma is common and exhibits distinct clinical outcomes.
Immune checkpoint inhibition (ICI) constitutes the first-line therapy for relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) despite low response rates. Some patients treated with ICI experience dissociated response (DR), the co-existence of responding and progression lesions. DR prevalence and prognosti...